Synexo Group (SYNEXO) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
15 May, 2026Business overview and growth strategy
Focuses on Backup-as-a-Service (BaaS) with high recurring revenue and low churn, serving over 1,000 customers and leveraging a reseller-led model for scalability.
Achieved 90% year-over-year pro forma ARR growth to SEK 6.4m in April 2026, with total signed ARR at SEK 10.65m and a net retention rate of ~117%.
Maintains a lean organization with ~3.5 FTEs, supporting significant ARR growth without major cost increases.
Operates with no interest-bearing debt, SEK 1.3m cash, and expects to be cash positive by end of H1 2026.
Targets >20% average organic annual growth and >70% gross margin, with profits reinvested in accretive M&A or distributed to shareholders.
Market opportunity and competitive positioning
Global BaaS market projected to grow at ~31.8% CAGR, reaching USD 33.18bn by 2030, driven by data growth, cybersecurity, and cloud migration.
Holds a strong position in the Nordic market, with both direct clients and a network of resellers, and is licensed to serve health and public sectors.
Competitive edge includes packaged service offerings, high customer satisfaction, and a focus on data security, resulting in low churn and high market share growth.
Industry characterized by outdated competitors, allowing for differentiation through modern, scalable solutions.
Financial performance and outlook
Pro forma operational Cash-EBITDA improved, with subsidiaries cash-flow positive and self-funded.
Cash-EBITDA expected to turn positive in Q2 2026, with break-even at SEK 6.7m ARR and favorable working capital dynamics.
Illustrative 2027 targets include ARR of SEK 60.8m and run-rate EBITDAC margin above 40%.
Trading at ~16.6x run-rate Cash EBITDA, with a 2027 ambition of >SEK 20m run-rate Cash EBITDA, implying a multiple of ~3x.
Latest events from Synexo Group
- ARR up 76% YoY, gross margin at 66%, and positive subsidiary EBITDA; M&A pipeline advancing.SYNEXO
Q1 202615 May 2026 - ARR up 61% y/y, strong upsell, low churn, and M&A activity drive growth and margin targets.SYNEXO
Q4 202526 Feb 2026 - Strong organic growth, high margins, and disciplined M&A drive scalable, shareholder-focused value.SYNEXO
Investor Presentation2 Jan 2026 - Q3 2025 delivered 56% pro forma revenue growth, 63% gross margin, and strong ARR expansion.SYNEXO
Q3 202528 Nov 2025 - No operations remain after subsidiary sale; future depends on a pending data storage acquisition.SYNEXO
Q2 202521 Aug 2025 - Sales dropped sharply and losses deepened, with recovery delayed to 2025/2026.SYNEXO
Q3 202413 Jun 2025 - Net sales dropped 43.6% and a SEK 2.6 million order was secured from Pathogen Systems Inc.SYNEXO
Q2 202413 Jun 2025 - Sales up, losses persist; MedTech order and new partnerships drive future focus.SYNEXO
Q1 20256 Jun 2025 - Omsättning föll 39% och fortsatt förlust kräver ny finansiering och omstrukturering.SYNEXO
Q4 20245 Jun 2025